Alkem Laboratories Shares Slump On USFDA Observations
The Mumbai-based pharmaceuticals company said the US health regulator had conducted an inspection at the Ankleshwar facility from December 5 to December 9.12-12-2016
12-12-2016
Update on US FDA Inspection at Alkems Ankleshwar API Facility
Alkem Laboratories Ltd has informed BSE that US FDA had conducted an inspection at the Companys API (Active Pharmaceutical Ingredient) manufacturing facility located at Ankleshwar, India from 5th December to 9th December, 2016.In this regard, the Company has received the inspection report which contains three 483 observations. The Company shall put together a detailed response with adequate corrective and preventive measures to address the...12-12-2016
Alkem Laboratories Limited
Alkem Laboratories has received tentative approval from the US Federal Drug Administration for the generic of Lyrica (Pregabalin) in 75mg, 100mg, 150mg, 200mg, 225mg and 300mg, details on the...02-12-2016
Fixes Record Date for Interim Dividend
Alkem Laboratories Ltd has informed BSE that the Company has fixed November 24, 2016 as the Record Date for the purpose of Payment of Interim Dividend.11-11-2016
Opening of Trading Window
Alkem Laboratories Ltd has informed BSE regarding "Opening of Trading Window".11-11-2016
Board declares Interim Dividend
Alkem Laboratories Ltd has informed BSE that the Board of Directors of the Company at its meeting held on November 11, 2016, have declared Interim Dividend of Rs. 6/-per equity share on the face value of Rs. 2/- per share for the financial year 2016-17. The date of payment of Interim dividend shall be on & From November 28, 2016.11-11-2016
Standalone & Consolidated Financial Results, Limited Review Report for September 30, 2016
Alkem Laboratories Ltd has informed BSE about : 1. Standalone Financial Results for the period ended September 30, 20162. Consolidated Financial Results for the period ended September 30, 20163. Standalone Limited Review for the period ended September 30, 20164. Consolidated Limited Review for the period ended September 30, 201611-11-2016
Intimation of Conference Call on Q2 FY17 Results
Alkem Laboratories Ltd has informed BSE regarding "Intimation of Conference Call on Q2 FY17 Results".07-11-2016
Update on the US FDA Bio-analytical Inspection at Alkems Daman Facility
Alkem Laboratories Ltd has informed BSE that the US FDA had conducted a Bio-analytical Inspection at the Companys manufacturing facility located at Daman, India from October 24 to October 28, 2016. The inspection has been cleared successfully without any 483 observations. This inspection was based on an ANDA filed by the Company.28-10-2016
Board to consider Interim Dividend
Alkem Laboratories Ltd has informed BSE that a meeting of the Board of Directors of the Company is scheduled to be held on November 11, 2016, inter-alia :- To consider and approve the Standalone and Consolidated Unaudited Financial Results of the Company for the quarter and half year ended September 30, 2016; and- To consider and approve Interim Dividend for the Financial Year 2016-2017.28-10-2016